Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oncolytic Virotherapy Mitigates the Selection of IFN-Resistant Tumor Cells Following Immunotherapy, Yet Faces Challenges from the Rise of Dedifferentiated Tumor Cells

  • By

  • Susan Gellert

  • Bastian Kruse

  • Johannes Peters

  • Susanne Bonifatius

  • Thomas Tüting

  • Anthony C. Buzzai

  • June 22, 2026

Share

  • 1

    Genetic mutations disrupting interferon signaling allow tumor cells to evade immune checkpoint inhibitor therapy.

  • 2

    Oncolytic virotherapy can specifically target and eliminate IFN-unresponsive tumor cell subclones.

  • 3

    Natural Killer cells eliminate IFN-unresponsive subclones in mixed tumor cell transplants due to low MHC-I expression.

  • 4

    Following immunotherapy, dedifferentiated IFN-responsive tumor cells can re-emerge, resisting both immune and viral control.

  • 5

    The findings highlight the dual role of cancer cell-intrinsic IFN signaling in tumor resistance mechanisms.

Original Source(s)

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells

  • by Susan Gellert, Bastian Kruse, Johannes Peters, Susanne Bonifatius, Thomas Tüting, Anthony C. Buzzai

  • June 22, 2026

Related Content

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

Genetic Testing in Retinoblastoma: New Applications

Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.